MAPT and Lewy body dementia: Interestingly, when comparing prodDLB and DLB patients, we observed a significant and gradual increase in CSF NfL levels in these subgroups (p = 0.01), Fig. 3A, while the levels of the core AD biomarkers (t-Tau, p-Tau and Aβ1–42) were comparable (data not shown).